Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Richard H. De Boer
Results From the First Multicenter, Open-Label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)
Clinical Breast Cancer
Cancer Research
Oncology
Related publications
Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib
AboutOpen
An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
Oncologist
Cancer Research
Medicine
Oncology
Estimated Life-Years Saved in Women With HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Relationship Between Tumor Biomarkers and Efficacy in MARIANNE, a Phase III Study of Trastuzumab Emtansine ± Pertuzumab Versus Trastuzumab Plus Taxane in HER2-positive Advanced Breast Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
Frontiers in Oncology
Cancer Research
Oncology
Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study
Journal of Clinical Pharmacology
Pharmacology
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE
Cancer
Cancer Research
Oncology
Trastuzumab in Combination With Metronomic Cyclophosphamide and Methotrexate in Patients With HER-2 Positive Metastatic Breast Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
